



PERGAMON

Journal of Steroid Biochemistry & Molecular Biology 86 (2003) III–VII

The Journal of
Steroid Biochemistry
&
Molecular Biology

www.elsevier.com/locate/jsbmb

List of Contents

JULY 2003

Vol. 86, No. 1

- Caroline Rousseau, Filippa Pettersson,
Marie-Claude Couture, Andre Paquin,
Jacques Galipeau, Sylvie Mader and
Wilson H. Miller Jr. 1 The N-terminal of the estrogen receptor (ER α) mediates transcriptional cross-talk with
the retinoic acid receptor in human breast cancer cells
- Aaron R. Ellison, Joan Lofing and Grant A. Bitter 15 Potentiation of human estrogen receptor α -mediated gene expression by steroid receptor
coactivator-1 (SRC-1) in *Saccharomyces cerevisiae*
- Kelli S. Bramlett and Thomas P. Burris 27 Target specificity of selective estrogen receptor modulators within human endometrial
cancer cells
- Shun-Ichi Tanaka, Mitsuru Kinowaki, Tada-Aki Eto,
Yoshikazu Ota, Yorio Maeda, Kyu-Ichiro Okuda,
Toshiaki Setoguchi and Kazuo Chijiwa 35 Sulfhydryl groups responsible for extreme lability of human cholesterol 7 α -hydroxylase
identified by site-directed mutagenesis
- Padmaja B. Thomas, Kelly E. Risinger and
Carolyn M. Klinge 41 Identification of estrogen receptor beta expression in Chinese hamster ovary (CHO) cells
and comparison of estrogen-responsive gene transcription in cells adapted to serum-free
media
- Ronald Gust and Veronika Lubczyk 57 Investigations on the influence of terminal groups at the C2-propyl side chain of 1,1-bis
(4-hydroxyphenyl)-2-phenylpent-1-ene and 1,1,2-tris(4-hydroxyphenyl)pent-1-ene on
the estrogen receptor binding and the estrogenic/anti-estrogenic properties
- Charlotte Atkinson, Heather E. Skor,
E. Dawn Fitzgibbons, Delia Scholes, Chu Chen,
Kristiina Wähälä, Stephen M. Schwartz and
Johanna W. Lampe 71 Urinary equol excretion in relation to 2-hydroxyestrone and 16 α -hydroxyestrone con-
centrations: an observational study of young to middle-aged women
- Stephan Steckelbroeck, Matthias Watzka,
Annette Reissinger, Petra Wegener-Toper,
Frank Bidlingmaier, Niklaas Bliesener,
Volkmar H.J. Hans, Hans Clusmann,
Michael Ludwig, Lothar Siekmann and
Dietrich Klingmüller 79 Characterisation of estrogenic 17 β -hydroxysteroid dehydrogenase (17 β -HSD) activity in
the human brain
- Dalia Somjen and Israel Yoles 93 DT56a (Tofupill[®]/Femarelle[™]) selectively stimulates creatine kinase specific activity
in skeletal tissues of rats but not in the uterus
- Mark J. McVey and Gerard M. Cooke 99 Inhibition of rat testis microsomal 3 β -hydroxysteroid dehydrogenase activity by
tributyltin
- Rapid communication*
- Paolo Carlini, Gianluigi Ferretti,
Serena Di Cosimo, Elvira Colella,
Riccardo Tonachella, Adriana Romiti,
Silverio Tomao, Antonio Frassoldati,
Paola Papaldo, Alessandra Fabi,
Enzo Maria Ruggeri and Francesco Cognetti 107 Is there a benefit by the sequence anastrozole–formestane for postmenopausal metastatic
breast cancer women?
- Erratum*
- H.J. Kloosterboer and A.G.H. Ederveen 111 Erratum to “Pros and cons of existing treatment modalities in osteoporosis: a comparison
between tibolone, SERMs and estrogen (\pm progestogen) treatments” [J. Steroid Bio-
chem. Mol. Biol. 83 (2003) 157–165]

AUGUST 2003

Vol. 86, No. 2

- Jens C. Brüning, Philipp Lingohr,
Jennifer Gillette, Bettina Hanstein,
Haluk Avci, Wilhelm Krone,
Dirk Müller-Wieland and Jörg Kotzka
- 113 Estrogen receptor- α and Sp1 interact in the induction of the low density lipoprotein-receptor
- Isabelle Martineau, Alain Bélanger,
André Tchernof and Yves Tremblay
- 123 Molecular cloning and expression of guinea pig cytochrome P450c21 cDNA (steroid 21-hydroxylase) isolated from the adrenals
- M.A. Kraevskaya, M.J.P. Higgins,
M.T. Wilson and D.B. Gower
- 133 Binding of the pheromonal steroid, 5 α -androst-16-en-3-one, to membrane-enriched fractions of boar and rat olfactory epithelium; preliminary evidence for binding protein being a glycoprotein
- Ashok R. Bapat and Donald E. Frail
- 143 Full-length estrogen receptor α and its ligand-binding domain adopt different conformations upon binding ligand
- Irma Villalpando and Victoria López-Olmos
- 151 Insulin-like growth factor I (IGF-I) regulates endocrine activity of the embryonic testis in the mouse
- Robert T. Chatterton Jr., Angela S. Geiger,
Peter H. Gann and Seema A. Khan
- 159 Formation of estrone and estradiol from estrone sulfate by normal breast parenchymal tissue
- Maria Rita Mariani, Elisabetta M. Carpaneto,
Massimo Ulivi, Vincent G. Allfrey and
Lidia C. Boffa
- 167 Correlation between butyrate-induced histone hyperacetylation turn-over and *c-myc* expression
- Carine Cueille, Stéphane Frayon,
Marie-Christine de Vernejoul and
Jean-Michel Garel
- 173 Dexamethasone decreases phospholipase C β 1 isozyme expression in human vascular smooth muscle cells
- D. Seidlová-Wuttke, T. Becker, V. Christoffel,
H. Jarry and W. Wuttke
- 179 Silymarin is a selective estrogen receptor β (ER β) agonist and has estrogenic effects in the metaphysis of the femur but no or antiestrogenic effects in the uterus of ovariectomized (ovx) rats
- Y.T. Ho, S.P. Newman, A. Purohit, M.P. Leese,
B.V.L. Potter and M.J. Reed
- 189 The effects of 2-methoxy oestrogens and their sulphamoylated derivatives in conjunction with TNF- α on endothelial and fibroblast cell growth, morphology and apoptosis
- T. Kalme, H. Koistinen, M. Loukovaara,
R. Koistinen and P. Leinonen
- 197 Comparative studies on the regulation of insulin-like growth factor-binding protein-1 (IGFBP-1) and sex hormone-binding globulin (SHBG) production by insulin and insulin-like growth factors in human hepatoma cells
- Teet Seene, Priit Kaasik, Ando Pehme,
Karin Alev and Eva-Maria Riso
- 201 The effect of glucocorticoids on the myosin heavy chain isoforms' turnover in skeletal muscle
- Miguel Coca-Prados, Sikha Ghosh,
Yugang Wang, Julio Escribano,
Annakaisa Herrala and Pirkko Vihko
- 207 Sex steroid hormone metabolism takes place in human ocular cells

SEPTEMBER 2003

Vol. 86, Nos. 3-5

- Hironobu Sasano, Mitch Dowsett
and Jorge R. Pasqualini
- 217 Preface
- Aromatase Molecular Structure and Control*
- Serdar E. Bulun, Siby Sebastian,
Kazuto Takayama, Takashi Suzuki,
Hironobu Sasano and Makio Shozu
- 219 The human *CYP19* (aromatase P450) gene: update on physiologic roles and genomic organization of promoters
- E.R. Simpson
- 225 Sources of estrogen and their importance

Shiuan Chen, Fangming Zhang, Mark A. Sherman, Ikuko Kijima, Michael Cho, Yate-Ching Yuan, Yoshiro Toma, Yoshio Osawa, Dujin Zhou and Elizabeth T. Eng	231	Structure–function studies of aromatase and its inhibitors: a progress report
H. Sasano, D.P. Edwards, T.J. Anderson, S.G. Silverberg, D.B. Evans, R.J. Santen, P. Ramage, E.R. Simpson, A.S. Bhatnagar and W.R. Miller	239	Validation of new aromatase monoclonal antibodies for immunohistochemistry: progress report
<i>Pharmacology and Effectiveness of Aromatase Inhibitors (AIs)</i>		
Jürgen Geisler	245	Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators
M. Dowsett and B.P. Haynes	255	Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interac- tion with tamoxifen
Wei Yue, Ji-Ping Wang, Mark R. Conaway, Yuebai Li and Richard J. Santen	265	Adaptive hypersensitivity following long-term estrogen deprivation: involvement of multiple signal pathways
Per Eystein Lønning	275	Comparison between aromatase inhibitors and sequential use
Angela H. Brodie, Danijela Jelovac and Brian Long	283	The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens
<i>Aromatase Inhibitors versus Tamoxifen</i>		
Ian E. Smith	289	Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neo- adjuvant therapy
<i>Neoadjuvant Comparisons of Aromatase Inhibitors and Tamoxifen</i>		
J.M. Dixon, J. Jackson, L. Renshaw and W.R. Miller	295	Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes
Matthew J. Ellis, Eric Rosen, Holly Dressman and Jeffery Marks	301	Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determi- nants of response and on-treatment effect
R. Charles Coombes, L. Gibson, E. Hall, M. Emson and J. Bliss	309	Aromatase inhibitors as adjuvant therapies in patients with breast cancer
James N. Ingle and Vera J. Suman	313	Aromatase inhibitors versus tamoxifen for management of postmenopausal breast cancer in the advanced disease and neoadjuvant settings
J.M. Nabholz, Arimidex Study Group	321	Advanced breast cancer updates on anastrozole versus tamoxifen
<i>Reproduction</i>		
Nobuhiro Harada, Noriko Yoshimura and Shin-ichiro Honda	327	Unique regulation of expression of human aromatase in the placenta
S. Bourguiba, C. Genissel, S. Lambard, H. Bouraïma and S. Carreau	335	Regulation of aromatase gene expression in Leydig cells and germ cells
Leo Dunkel and Sanna Wickman	345	Novel treatment of short stature with aromatase inhibitors
<i>Comparative Biology and Behavioral Aspects</i>		
Takahiro Matsumoto, Shin-ichiro Honda and Nobuhiro Harada	357	Neurological effects of aromatase deficiency in the mouse
Jacques Balthazart, Michelle Baillien, Thierry D. Charlier, Charlotte A. Cornil and Gregory F. Ball	367	Multiple mechanisms control brain aromatase activity at the genomic and non-genomic level
Sok-Keng Tong and Bon-chu Chung	381	Analysis of zebrafish <i>cyp19</i> promoters

Lessons from Models of Aromatase Deficiency

- Kenneth S. Korach, Judith M.A. Emmen, Vickie R. Walker, Sylvia C. Hewitt, Mariana Yates, Julie M. Hall, Deborah L. Swope, Joshua C. Harrell and John F. Couse** 387 Update on animal models developed for analyses of estrogen receptor biological activity

- Toshihiko Yanase, Shizu Suzuki, Kiminobu Goto, Masatoshi Nomura, Taijiro Okabe, Ryoichi Takayanagi and Hajime Nawata** 393 Aromatase in bone: roles of Vitamin D₃ and androgens

Adjuvant Trials in Breast Cancer

- Aman U. Buzdar, On behalf of ATAC trialists group** 399 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer—efficacy overview

- Valerie Shilling, Valerie Jenkins, Lesley Fallowfield and Tony Howell** 405 The effects of hormone therapy on cognition in breast cancer

Key-note Lecture

- W.R. Miller, T.J. Anderson, D.B. Evans, A. Krause, G. Hampton and J.M. Dixon** 413 An integrated view of aromatase and its inhibition

Alternative Approaches to Therapy

- A. Purohit, L.W.L. Woo, S.K. Chander, S.P. Newman, C. Ireson, Y. Ho, A. Grasso, M.P. Leese, B.V.L. Potter and M.J. Reed** 423 Steroid sulphatase inhibitors for breast cancer therapy

- Shin-ichi Hayashi, Takako Sakamoto, Akio Inoue, Nobuyuki Yoshida, Yoko Omoto and Yuri Yamaguchi** 433 Estrogen and growth factor signaling pathway: basic approaches for clinical application

Experience in Anti-aromatase Agents for Combination Therapy in Breast Cancer

- Louis W.C. Chow, Joyce L.N. Wong and Masakazu Toi** 443 Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report

Estrogen Sulfatase and its Inhibition in Breast Cancer

- Takashi Suzuki, Yasuhiro Miki, Taisuke Nakata, Yukimasa Shiotsu, Shiro Akinaga, Kengo Inoue, Takanori Ishida, Michio Kimura, Takuya Moriya and Hironobu Sasano** 449 Steroid sulfatase and estrogen sulfotransferase in normal human tissue and breast carcinoma

- Taisuke Nakata, Shigemitsu Takashima, Yukimasa Shiotsu, Chikara Murakata, Hiroyuki Ishida, Shiro Akinaga, Pui-Ki Li, Hironobu Sasano, Takashi Suzuki and Toshiaki Saeki** 455 Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients

Aromatase Excess

- Roopa Luthra, Nameer Kirma, Jeremy Jones and Rajeshwar Rao Tekmal** 461 Use of letrozole as a chemopreventive agent in aromatase overexpressing transgenic mice

- Xiangdong Li, Sari Mäkelä, Tomi Streng, Risto Santti and Matti Poutanen** 469 Phenotype characteristics of transgenic male mice expressing human aromatase under ubiquitin C promoter

- W. Yue, R.J. Santen, J.-P. Wang, Y. Li, M.F. Verderame, W.P. Bocchinfuso, K.S. Korach, P. Devanesan, R. Todorovic, E.G. Rogan and E.L. Cavalieri** 477 Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis

Breast Cancer Prevention

- Paul E. Goss** 487 Breast cancer prevention—clinical trials strategies involving aromatase inhibitors

G.L.S. Davies	495	Cyclooxygenase-2 and chemoprevention of breast cancer
Robert W. Brueggemeier, Jeanette A. Richards and Trevor A. Petrel	501	Aromatase and cyclooxygenases: enzymes in breast cancer
	III	List of Contents to Vol. 86
	IX	Subject index to Vol. 86
	XIII	Author index to Vol. 86